Only 5% of these US specialists say their practices plan to hold off until Labor Day or later before resuming elective procedures.
Yet only 40% say that their facilities are prepared for a second wave or any local outbreaks caused by the states re-opening.
These are findings from the InCrowd Novel Coronavirus (COVID-19) Non-Frontline Treating Physician Tracking Report--Wave 2, a snapshot of US physician sentiments from oncologists, neurologists, rheumatologists, cardiologists, gastroenterologists, and dermatologists conducted and sourced by InCrowd, a provider primary market intelligence for the life science industry.
With recent spikes in COVID-19 cases forcing curtailment to elective procedures in some hard-hit communities, InCrowd's new findings document significant care delivery progress along with lingering perceived issues in governmental preparedness.
Fifty-four percent reported that their facilities are currently strongly prepared to treat COVID-19 patients.
Physician concerns over personal/familial safety and markers of mental health have all improved significantly since April, with concerns over safety dropping by over 20 %age points, to 48% of respondents, down from 71% in April. Concerns related to job security reducing by over a third, to 13% of respondents, down from 22% in April.
The number of specialists experiencing frequent patient cancellations for routine appointments has dropped by nearly half of what was reported in April, to just 37% in June, from 73% in April. Fewer physicians noted difficulty in prescribing medications for patients, compared to 20% in April.
Ninety-one percent use virtual visits or telehealth TODAY, and more than a third said they plan on using telehealth for routine appointments moving forward.
Nearly 30% plan to use it for preparatory appointments for upcoming surgeries and 26% will use telehealth for screening patients for urgent visits.
However, only 46% said their increased use of telehealth is likely to continue after the crisis is over, down slightly from 52% in April.
A third of specialists write-in that in order to make patients feel safe, their facilities require a negative COVID-19 test before admitting anyone. More than two-thirds report they are planning to continue practicing better hygiene, limit physical contact such as handshakes, require social distancing, and screen patients before visits.
In verbatim remarks physicians emphasized rigorous sanitization and other changed office practices they share with patients to keep them safe--from "advising [patients] of the number of patients at the height of COVID in hospital and [the] number now," to "asking patients to comply with pre-procedural [COVID-19] testing."
Overall, non-frontline physicians do not find that the US is taking sufficient precautions, with approval of the federal government's management of the pandemic at 18%, nearly half that of international governments.
Only one-in-five believes the US has the ability to flatten the curve. Respondents were more bullish on their state government and local government preparedness.
Meetings with pharma sales reps will be limited or deferred, despite 18% of respondents saying that COVID-19 has made it more difficult to become aware of medications that could help their patients.
Only 22% envision booking telehealth-style virtual meetings with pharma reps, with 31% expecting to wait until 2021 before allowing in-person meetings.
On average, non-frontline physicians estimate that things will not return to normal for another nine months--not until March of next year. One third cite that disruptions will continue until a vaccine is developed and disseminated.
InCrowd's Novel Coronavirus (COVID-19) Non-Frontline Treating Physician Tracking Report--Wave 2, included the perceptions of n=201 US physicians, including 103 practicing in offices, and 98 practicing in hospitals.
Total respondents included oncologists, neurologists, rheumatologists, gastroenterologists, cardiologists, and dermatologists. The 7-minute MicroSurvey for Wave 2 fielded June 12-13, 2020.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine